HC Wainwright Issues Positive Forecast for GPCR Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for Structure Therapeutics in a research report issued on Tuesday, May 12th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($0.37) for the quarter, up from their previous estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($1.32) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.47) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($1.92) EPS, FY2029 earnings at ($2.05) EPS and FY2030 earnings at ($1.99) EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04.

Several other equities research analysts also recently issued reports on the company. Wolfe Research initiated coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. JPMorgan Chase & Co. raised their price target on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Finally, BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Trading Up 0.6%

NASDAQ:GPCR opened at $38.08 on Thursday. The firm has a fifty day simple moving average of $49.79 and a 200 day simple moving average of $56.44. Structure Therapeutics has a 1-year low of $15.80 and a 1-year high of $94.90. The stock has a market capitalization of $2.70 billion, a PE ratio of -43.77 and a beta of -1.31.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GPCR. Aberdeen Group plc grew its position in Structure Therapeutics by 46.1% in the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after acquiring an additional 185,245 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Structure Therapeutics in the third quarter valued at about $4,770,000. Private Capital Advisors Inc. bought a new position in Structure Therapeutics in the third quarter valued at about $1,545,000. Capricorn Fund Managers Ltd bought a new position in Structure Therapeutics in the fourth quarter valued at about $17,568,000. Finally, Janney Capital Management LLC bought a new position in Structure Therapeutics in the third quarter valued at about $384,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.